➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,553,828

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,553,828 protect, and when does it expire?

Patent 7,553,828 protects NUZYRA and is included in two NDAs.

This patent has eighty-two patent family members in twenty-three countries.

Summary for Patent: 7,553,828
Title:9-aminomethyl substituted minocycline compounds
Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
Inventor(s): Nelson; Mark L. (Norfolk, MA), Frechette; Roger (Reading, MA), Ismail; Mohamed Y. (Bedford, MA), Honeyman; Laura (Roslindale, MA), Bowser; Todd (Charlton, MA), Bhatia; Beena (Arlington, MA)
Assignee: Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:10/786,881
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 7,553,828

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,553,828

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 336481   Start Trial
Austria 544745   Start Trial
Australia 2001286388   Start Trial
Australia 2003220123   Start Trial
Australia 2005201623   Start Trial
Australia 2009201857   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.